GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 2, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, company-disclosure
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 2, 2025, that it has purchased a number of its own ordinary shares, acting through its broker, BNP Paribas SA. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- BNP Paribas SA (company) — The broker acting on behalf of GSK plc for the share purchase.
- October 2025 (date) — The period during which the transactions occurred.
FAQ
What was the total number of GSK plc ordinary shares purchased?
The filing states that a 'number' of ordinary shares were purchased but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount of the share repurchases.
On what date was this transaction report filed?
This report was filed on October 2, 2025.
Who acted as the broker for GSK plc in this transaction?
BNP Paribas SA acted as the broker for GSK plc.
What is the par value of GSK plc's ordinary shares?
The ordinary shares have a par value of 31 1/4 pence each.
Filing Stats: 3,067 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-02 06:51:18
Filing Documents
- a7193b.htm (6-K) — 4057KB
- 0001654954-25-011359.txt ( ) — 4058KB
From the Filing
IN OWN SHARES a7193b UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   01 October 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   262,000    Lowest price paid per share (GBp):   1,594.50p   Highest price paid per share (GBp):   1,670.00p   Volume-weighted average price paid per share (GBp):   1,626.49p     The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025.  Since 30 September 2025 the Company has purchased 567,000 ordinary shares.   Following the above purchase, the Company will hold 248,031,844 ordinary shares in treasury and have 4,067,375,496 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,067,375,496. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.10 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     01 October 2025 Investment firm:       BNP Paribas SA     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   27,801   1,670.00p   1,594.50p   1,628.14p   CHIX   85,599   1,670.00p   1,594.50p   1,628.68p   XLON   148,600   1,670.00p   1,594.50p   1,624.92p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   52   1595.0   XLON   01-Oct-2025   08:00:06   20251001145328349   94   1595.0   XLON   01-Oct-2025   08:00:06   20251001145328351   79   1595.0   XLON   01-Oct-2025   08:00:07   20251001145328373   253